Here are six things to know about the Globus Medical financial report:
1. The company’s worldwide sales reached $113.6 million. Net income was up to $20.6 million, compared to $7.4 million over the same period last year. “We are confident in our long term growth prospects and our ability to sustain our industry leading profitability by continued execution of our business model,” said CEO David Paul.
2. The United States net sales grew 3.6 percent while international sales grew 34.1 percent. Total sales were up 10.5 percent for the quarter.
3. The company ended the quarter with $313 million in cash, cash equivalents and marketable securities, which increased by $8.1 million during the quarter. Globus Medical is currently debt free.
4. Five new products were launched during the second quarter, including CREO Threaded, which offers controlled gradual correction for complex deformity users preferring threaded locking caps.
5. Earnings per diluted share were $0.22 in the quarter, up considerably from $0.08 in the second quarter of 2013. The company also reported Non-GAAP EPS at $0.23, up slightly from the same period last year.
6. The company now expects full year net sales to reach $460 million to $465 million with full year Non-GAAP diluted earnings per share guidance unchanged at $0.90 to $0.92 per share of common stock.
More articles on orthopedic devices:
Symmetry Medical to split & spine off: 5 things to know
Baxano Surgical gets 2 new patents for lateral spine surgery, AxiaLIF
Orthocell raises $8M in oversubscribed IPO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
